Urinary albumin-to-creatinine ratio values are often used to guide treatment decisions as albuminuria is known to be a strong predictor of cardiovascular and renal events.
A move toward combination therapies is inevitable in the new paradigm for diabetic kidney disease management, according to the authors of an editorial.
Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.